Research programme: antibodies - OstriGen

Drug Profile

Research programme: antibodies - OstriGen

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OstriGen
  • Developer Beth Israel Deaconess Medical Center; Kyoto Prefectural University of Medicine; Massachusetts General Hospital; OstriGen; United States Army Medical Research Institute of Infectious Diseases
  • Class Antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cholera; Clostridium-difficile-infections; Diarrhoea; Ebola virus infections; Escherichia coli infections; Norovirus infections; Salmonella infections; Shigella infections; Zika virus infection

Most Recent Events

  • 05 Dec 2016 Preclinical trials in Diarrhoea in Mozambique (PO)
  • 05 Dec 2016 Preclinical trials in Zika virus infection, Shigella infections, Salmonella infections, Norovirus infections, Escherichia coli infections, Ebola virus infections, Clostridium difficile infections, and Cholera in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top